Reproducibility and sensitivity of 36 methods to quantify the SARS-CoV-2 genetic signal in raw wastewater: findings from an interlaboratory methods evaluation in the U.S.

Citations Over TimeTop 1% of 2021 papers

Abstract

In response to COVID-19, the international water community rapidly developed methods to quantify the SARS-CoV-2 genetic signal in untreated wastewater. Wastewater surveillance using such methods has the potential to complement clinical testing in assessing community health. This interlaboratory assessment evaluated the reproducibility and sensitivity of 36 standard operating procedures (SOPs), divided into eight method groups based on sample concentration approach and whether solids were removed. Two raw wastewater samples were collected in August 2020, amended with a matrix spike (betacoronavirus OC43), and distributed to 32 laboratories across the U.S. Replicate samples analyzed in accordance with the project's quality assurance plan showed high reproducibility across the 36 SOPs: 80% of the recovery-corrected results fell within a band of ±1.15 log₁₀ genome copies per L with higher reproducibility observed within a single SOP (standard deviation of 0.13 log₁₀). The inclusion of a solids removal step and the selection of a concentration method did not show a clear, systematic impact on the recovery-corrected results. Other methodological variations (e.g., pasteurization, primer set selection, and use of RT-qPCR or RT-dPCR platforms) generally resulted in small differences compared to other sources of variability. These findings suggest that a variety of methods are capable of producing reproducible results, though the same SOP or laboratory should be selected to track SARS-CoV-2 trends at a given facility. The methods showed a 7 log₁₀ range of recovery efficiency and limit of detection highlighting the importance of recovery correction and the need to consider method sensitivity when selecting methods for wastewater surveillance.

Related Papers

• → And now for something completely different: from 2019-nCoV and COVID-19 to 2020-nMan(2020)27 cited
• → Realizing the Potential of Anti–SARS-CoV-2 Monoclonal Antibodies for COVID-19 Management(2022)21 cited
• → Confirmation of SARS-CoV-2 airborne dissemination indoors using “COVID-19 traps”(2021)4 cited
• → Fachinformationen zu SARS-CoV-2/COVID-19(2020)